These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27822967)

  • 21. Key targets and relevant inhibitors for the drug discovery of tuberculosis.
    Xiong X; Xu Z; Yang Z; Liu Y; Wang D; Dong M; Parker EJ; Zhu W
    Curr Drug Targets; 2013 Jun; 14(6):676-99. PubMed ID: 23547780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycobacterium tuberculosis proteases and implications for new antibiotics against tuberculosis.
    Zhao QJ; Xie JP
    Crit Rev Eukaryot Gene Expr; 2011; 21(4):347-61. PubMed ID: 22181704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitubercular drug development: current status and research strategies.
    Barot KP; Nikolova S; Ivanov I; Ghate MD
    Mini Rev Med Chem; 2013 Oct; 13(11):1664-84. PubMed ID: 23895192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell Surface Biosynthesis and Remodeling Pathways in Mycobacteria Reveal New Drug Targets.
    Shaku M; Ealand C; Kana BD
    Front Cell Infect Microbiol; 2020; 10():603382. PubMed ID: 33282752
    [No Abstract]   [Full Text] [Related]  

  • 25. Study of the bioenergetics to identify the novel pathways as a drug target against Mycobacterium tuberculosis using Petri net.
    Gupta S; Fatima Z; Kumawat S
    Biosystems; 2021 Nov; 209():104509. PubMed ID: 34461147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel targets in M. tuberculosis: search for new drugs.
    Lamichhane G
    Trends Mol Med; 2011 Jan; 17(1):25-33. PubMed ID: 21071272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research progresses of Mycobacterium tuberculosis cytochrome P450s as a potential drug target].
    Lu Y; Qiao F; You XF; Yang XY
    Yao Xue Xue Bao; 2014 Apr; 49(4):427-34. PubMed ID: 24974457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drugs for the treatment of Mycobacterium tuberculosis infection.
    AlMatar M; AlMandeal H; Var I; Kayar B; Köksal F
    Biomed Pharmacother; 2017 Jul; 91():546-558. PubMed ID: 28482292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Resistance to antitubercular drugs in Chile].
    Valenzuela MT; Scheel G; Ponce J; Lepe R; Velasco M; Valenzuela P
    Rev Med Chil; 1984 Jan; 112(1):76-80. PubMed ID: 6429808
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug resistance in tuberculosis.
    Parsons LM; Driscoll JR; Taber HW; Salfinger M
    Infect Dis Clin North Am; 1997 Dec; 11(4):905-28. PubMed ID: 9421707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycobacterium tuberculosis treatment modalities and recent insights.
    Sukhithasri V; Vinod V; Varma S; Biswas R
    Curr Drug Deliv; 2014; 11(6):744-52. PubMed ID: 24947482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential Drug Targets in Mycobacterial Cell Wall: Non-Lipid Perspective.
    Das S; Hameed S; Fatima Z
    Curr Drug Discov Technol; 2020; 17(2):147-153. PubMed ID: 29875004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets.
    Jankute M; Grover S; Rana AK; Besra GS
    Future Microbiol; 2012 Jan; 7(1):129-47. PubMed ID: 22191451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genes and regulatory networks involved in persistence of Mycobacterium tuberculosis.
    Wang X; Wang H; Xie J
    Sci China Life Sci; 2011 Apr; 54(4):300-10. PubMed ID: 21267668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron Acquisition Pathways as Targets for Antitubercular Drugs.
    Meneghetti F; Villa S; Gelain A; Barlocco D; Chiarelli LR; Pasca MR; Costantino L
    Curr Med Chem; 2016; 23(35):4009-4026. PubMed ID: 27281295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors of an essential mycobacterial cell wall lipase (Rv3802c) as tuberculosis drug leads.
    West NP; Cergol KM; Xue M; Randall EJ; Britton WJ; Payne RJ
    Chem Commun (Camb); 2011 May; 47(18):5166-8. PubMed ID: 21384024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance in tuberculosis.
    Ebrahim GJ
    J Trop Pediatr; 2007 Jun; 53(3):147-9. PubMed ID: 17526511
    [No Abstract]   [Full Text] [Related]  

  • 38. MmpS5/MmpL5 as an efflux pump in Mycobacterium species.
    Briffotaux J; Huang W; Wang X; Gicquel B
    Tuberculosis (Edinb); 2017 Dec; 107():13-19. PubMed ID: 29050760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach.
    Biava M; Porretta GC; Poce G; Battilocchio C; Alfonso S; de Logu A; Manetti F; Botta M
    ChemMedChem; 2011 Apr; 6(4):593-9. PubMed ID: 21341373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-Target Antitubercular Drugs.
    de Oliveira Viana J; Ishiki HM; Scotti MT; Scotti L
    Curr Top Med Chem; 2018; 18(9):750-758. PubMed ID: 29807515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.